Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "API"

2692 News Found

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Clinical Trials | October 01, 2025

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine


BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu
News | September 30, 2025

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price


Revvity launches AI-powered software to transform preclinical imaging analysis
Digitisation | September 30, 2025

Revvity launches AI-powered software to transform preclinical imaging analysis

The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities


DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
Biotech | September 29, 2025

DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland

The new site enables end-to-end production of viral vector gene therapies


Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025
Digitisation | September 29, 2025

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies


Aptar Pharma opens new R&D center in France
News | September 29, 2025

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world


AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs